Articles tagged with Lung Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers at TSRI will explore Notch signaling pathways as therapeutic options for non-small cell lung cancer. The grant aims to improve treatment outcomes for advanced disease, where survival rates remain poor despite falling death rates.
A combination of two drugs has successfully halted the growth of lung adenocarcinomas carrying KRAS mutations, a common genetic subtype of lung cancer. The treatment targets KRAS's accomplices rather than the gene itself, and its potential as a clinical trial is being explored.
The American Cancer Society and Stand Up To Cancer have announced a collaborative research effort focused on lung cancer, the leading cause of cancer mortality in the US. The $20 million Dream Team grant will be awarded to support the development of new therapies for lung cancer.
Researchers at the University of Colorado Cancer Center have identified shared genetic signatures between lung and bladder cancers, which may refine patient prognoses and treatment choices.
The European Society for Medical Oncology warns that Eastern Europe lacks sufficient data, highlighting the need for a unified system. Despite this, many Western European countries are expected to have enough medical oncologists to meet growing cancer demands by 2020.
Cancer death rates have declined by 20% over the past two decades, with middle-aged black men experiencing a 50% reduction in mortality. The American Cancer Society estimates that there will be 1,665,540 new cancer cases and 585,720 cancer deaths in 2014.
The US Preventive Services Task Force recommends annual low-dose computed tomography (LDCT) screening for high-risk adults between 55 and 80 years old. Heavy smokers or former heavy smokers who have quit within the past 15 years are considered high risk due to increased lung cancer risk. The recommendation is based on comprehensive evi...
A University of Colorado Cancer Center study found that ALK and ROS1 gene rearrangements, known to drive subsets of lung cancer, are also present in some colorectal cancers. This implies that drugs used to target ALK and ROS1 in lung cancer may have applications in treating a subset of colorectal cancer patients.
Death rates for lung cancer, colorectal, breast, and prostate cancers have been declining, driving a reduction in cancer deaths. However, some cancers, including liver and pancreas, saw increased death rates. Comorbid conditions also impact survival, with one-third of patients aged 65+ having multiple medical conditions.
New data from the NLST suggests that low-dose CT screening for lung cancer may overdiagnose up to 22% of non-small cell lung cancers. However, the rate is significantly lower than projected for other cancer screenings, supporting the implementation of lung cancer screening programs.
A recent study found that over 18% of lung cancers detected by low-dose computed tomography (LDCT) may be cases of overdiagnosis, where the cancer would not have become clinically apparent without screening. This could lead to unnecessary treatment, anxiety, and increased healthcare costs.
Researchers found that inhibiting antioxidant proteins reduced tumor growth and induced cell death in lung cancer cells. In a mouse model, the inhibitor ATN-224 also reduced tumor sizes when combined with another drug.
A special issue of the Journal of the American College of Radiology addresses imaging-based screening and radiology's role in preventive medicine. The issue explores breast density legislation, digital breast tomosynthesis, lung cancer screening, and CT colonography reimbursement, highlighting both benefits and controversies.
A University of Colorado Cancer Center study found that crizotinib treatment reduces kidney function in ALK positive non-small cell lung cancer patients. Kidney function recovered after treatment, but additional tests are recommended if concerns arise.
Researchers at UCSF have developed a new strategy to block the mutated ras protein, which drives three out of ten cancers, including lung and colon cancers. The small molecules efficiently kill ras-driven cancer cells in human lung cancer cell cultures.
Researchers found that inhibiting ion channel TRPC5 limits kidney filtration loss after injury, suggesting a new therapeutic target. The study demonstrates the protective effects of TRPC5 inhibition on kidney function and provides hope for treating kidney failure.
Researchers identified KDM2A as a histone demethylase associated with non-small cell lung cancer. Induced KDM2A expression increased cell proliferation and invasiveness through ERK1/2 signaling pathway activation.
Glen J. Weiss, MD, presents studies on TSR-011, a potent ALK and TRK inhibitor, and Ki67, a measure of cell proliferation, in non-small cell lung cancer (NSCLC) tumors collected before chemotherapy and after surgery. These studies show preliminary clinical activity against various tumor types.
A Phase 1B study of MK-3475, an anti-PD-1 immunotherapy drug, showed encouraging results in treating non-small cell lung cancer, with a 24% response rate and median overall survival of 51 weeks. The drug, developed by Merck, allows the immune system to detect and attack cancer cells.
Dr. Avrum Spira has received the Alton Ochsner Award for his seminal research contributions to understanding the biological response of lung tissue to tobacco smoke. His work has led to the development of early detection biomarkers for lung cancer and molecular biomarkers for COPD treatment guidance.
The Cell-CT platform detected lung cancer in patient sputum samples with a sensitivity of over 95% and specificity of 99.8%. The technology creates comprehensive 3D digital images of cells, making it possible to determine the presence or absence of cancer with great accuracy.
Researchers developed a breath-based test to detect lung cancer using a colorimetric sensor array that detects unique chemical signatures. The test accurately distinguished breath samples from people with lung cancer from controls.
A study at Dana-Farber Cancer Institute discovered a gene fusion that fuels the growth of some lung adenocarcinomas, making targeted therapies effective for patients with specific genetic changes. The finding suggests that drugs targeting NTRK1's protein product could be effective in treating these patients.
Researchers at Boston University School of Medicine have discovered a regulatory molecule, miR-4423, that is less abundant in people with lung cancer and inhibits lung cancer cell growth. This molecule may aid in diagnosing lung cancer in earlier stages and treating the disease when at healthy levels.
Researchers at Penn Medicine found that focusing on factors like hope, randomization, and altruism can increase patient willingness to participate in clinical trials for malignant pleural mesothelioma. The study showed a significant increase in participation rates when physicians spent more time discussing these factors with patients.
Researchers found metformin as an effective radiosensitizer for treating stage III non-small cell lung cancer, improving local control and overall survival. The study suggests combining metformin with chemotherapy and radiation therapy may be a promising treatment approach.
As people age, gene mutations and epigenetic changes accumulate, increasing cancer risk. Researchers will examine the role of epigenetics in lung cancer development, seeking new biomarkers to predict cancer risk.
PF-06463922, a new investigational drug, has shown potent activity against the ALK protein kinase and its mutants, including those resistant to crizotinib. This offers a potential treatment option for patients with lung cancer harboring ALK gene abnormalities.
Researchers discovered 127 genes that appear to drive the development of a range of tumors in the body across 12 major cancer types. The study found common links among genes in different cancers, as well as mutations exclusive to particular cancer types.
The International Association for the Study of Lung Cancer (IASLC) awarded five people Advocacy Travel Awards to support their attendance at the 2013 World Conference on Lung Cancer in Sydney. The awards provide conference registration, accommodations, a free IASLC Membership, and a travel stipend.
A study suggests that Indi's blood test can accurately distinguish between benign lung nodules and early-stage lung cancer by detecting a specific combination of proteins in the blood. The test, powered by advanced protein detection technology, has a 90% accuracy rate and could complement current clinical risk factors.
PET scans can identify patients with more aggressive tumors, enabling intensified treatment for locally advanced lung cancer. The study found a strong correlation between radiation dose intensity and local control of the cancer.
A phase I clinical trial has shown that an anti-PD-L1 monoclonal antibody can produce striking responses in non-small cell lung cancer patients with metastatic disease who have failed to respond to previous chemotherapy. Smokers and former smokers are more likely to benefit from this treatment.
Researchers at Ohio State University have discovered that high levels of microRNA-31 in primary tumor cells predict lymph node metastasis and poor survival in patients with non-small cell lung cancer. Low expression levels were associated with excellent survival.
The study found a significantly lower quality of life in patients who received high-dose radiation therapy (74 Gy) compared to those receiving standard dose (60 Gy). IMRT was associated with a lower decline in QOL compared to 3-D CRT, even a year after treatment.
UT Southwestern researchers discover that a protein overactivity sabotages cellular recycling, leading to heightened cancer growth and chemotherapy resistance. Autophagy inhibition may worsen chemotherapy outcomes for patients with specific cancer mutations, according to the study published in Cell.
Researchers from RIKEN Center for Life Science Technologies identified a genetic mutation associated with improved survival rates in lung cancer patients who do not smoke. The mutation affects the NRF2 gene, which protects cells from oxidative stress.
A University of Colorado Cancer Center study found that current ALK-positive lung cancer criteria may miss patients who could benefit from crizotinib. The researchers suggest that doctors should re-evaluate borderline or atypical cases, potentially expanding treatment eligibility.
Researchers have developed a cheap and non-invasive breath test to diagnose lung cancer, which has been shown to correctly identify lung cancer patients with high sensitivity. The technique uses an electronic nose to detect volatile organic compounds in exhaled breath samples.
A new publication by the European Respiratory Society reveals that lung conditions account for 12.5% of EU deaths, with annual costs totaling at least 390 billion Euros. The White Book estimates direct and indirect costs due to lung diseases are around 400 billion Euros annually.
A prospective cohort study of 81,697 racially diverse adults found that lung cancer survival between black and white patients was similar when demographic factors and smoking were controlled. The study aimed to address racial disparities in lung cancer survival rates.
A new clinical risk calculator software has been developed to accurately classify benign and malignant spots on lung scans of smokers. The software uses a prediction model that considers several factors, including size, age, family history, and location of the nodule, to predict the probability of cancer.
A new set of evidence-based guidelines recommend lung cancer screening for high-risk populations in Ontario using low-dose computed tomography (LDCT). The guidelines suggest annual screening for two years, followed by biennial screenings until a negative result is obtained. The recommended parameters for LDCT include 120 to 140 kVp and...
Researchers recommend accelerated radiotherapy as standard treatment for un-resected non-small cell lung cancer patients not receiving concurrent chemo-radiotherapy, citing its efficiency over current practice. However, cost-effectiveness of different modified schemes remains uncertain and requires further research.
Researchers found that Notch 1 is required for initial tumor growth and survival of cancer cells. Disabling Notch 1 leads to increased cancer cell death through increased p53 stability.
A study led by UT Southwestern Medical Center researchers found that total tumor measurements greater than 3 inches predict shorter survival times in advanced lung cancer patients. Patients with larger tumors live an average of 9.5 months, compared to 12.6 months for those with smaller tumors.
Researchers at Moffitt Cancer Center identified four genetic variants associated with increased risk of death in non-small cell lung cancer patients. These variants also indicate a greater risk of death if treatment plans include surgery without chemotherapy compared to those with chemotherapy following surgery.
Researchers found that a specific pattern in tumor pathology is strongly associated with cancer recurrence. Patients with this pattern are more likely to benefit from lobectomy and have a 75% lower risk of recurrence. The study may lead to new technology to precisely identify tumors with this pattern before surgery.
Researchers at Fred Hutchinson Cancer Center are pioneering a new approach to harness the power of the adaptive immune system to control cancer. They are using high-throughput technology and large-scale data mining to identify potential immune targets and verify their immunogenicity.
Screening asymptomatic high-risk adults for lung cancer using low-dose computed tomography (LDCT) may significantly reduce mortality, according to a systematic review. The US Preventive Services Task Force reviewed 67 articles and found that LDCT screening can detect lung cancer at an earlier stage, leading to lower mortality rates.
Researchers in Canada found that funding from the pharmaceutical industry significantly decreased EGFR mutation testing after it was discontinued. The Canadian healthcare system lacked resources for implementing a national policy, leading to a substantial drop in test requests.
Researchers have identified Ephrin B2 as a promising target for treating malignant pleural mesothelioma, a rare and aggressive form of lung cancer. The study found that EPHB2 is significantly overexpressed in tumor tissue compared to normal peritoneum, suggesting its potential as a biomarker for early diagnosis and treatment.
Researchers found that obese patients initially had superior outcomes in terms of overall survival compared to normal-weight and overweight patients. However, their risk of death from any cause significantly increased once they were on the study longer than 16 months, indicating a limited time benefit of obesity in lung cancer patients.
Researchers at Moffitt Cancer Center discovered a gene expression signature that may lead to new immune therapies for lung cancer patients. High levels of NF-κB in lung cancer tumors can act as a suppressor, boosting the immune system to eliminate cancerous cells.
A study by Weill Cornell Medicine found that even healthy-looking smokers have damaged airway cells with characteristics similar to those in aggressive lung cancer. The researchers discovered that these cells express human embryonic stem cell genes, which are normally only active in developing embryos.
A European-wide study found that prolonged exposure to particulate air pollution increases the risk of lung cancer, particularly adenocarcinoma, at concentrations below EU limit values. The analysis of 17 cohort studies involved over 313,000 people and found a strong association between air pollution and lung cancer risk.
The foundation awarded six new Clinical Investigators, including Omar Abdel-Wahab and Himisha Beltran, for their cancer research programs. The recipients will receive $450,000 each, while three others received Continuation Grants worth $300,000 to support ongoing research.
Researchers have developed two new methodologies to determine ALK status in non–small-cell lung cancer (NSCLC) patients. The first method improves IHC assay sensitivity using a novel hapten and tyramide amplification, detecting low levels of ALK protein expression. The second method combines brightfield IHC with in situ hybridization f...
Researchers developed a highly accurate method to detect ALK-rearranged non-small cell lung cancer using immunocytochemistry. The study found that this method had high sensitivity and specificity, making it suitable for prescreening NSCLC patients.
Anurag Singh, PhD, has received a $100,000 ALA Lung Cancer Discovery Grant to study targeted therapies for drug-resistant lung cancers. He aims to develop strategies to block KRAS protein function and improve treatment outcomes.